Clinical trials: Non-Hodgkin Lymphomas
B Cell Lymphoma, Follicular Lymphoma
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
Patients undergo chemotherapy until remission is obtained, or disease has been stable for two cycles of chemotherapy, or progressive disease develops.
- Conditions
- B Cell Lymphoma, Follicular Lymphoma, Neoplasm
- Trial name
- NCT00001572
- Testing
- Id-KLH Vaccine, QS-21 (Stimulation-QS-21) Drug
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion Lymphoma
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
Background: The chemotherapy combination DA-EPOCH-RP includes the drugs etoposide (E), prednisone (P), vincristine (O), cyclophosphamide (C), doxorubicin (H), rituximab (R), and pomalidomide (P).
- Trial name
- NCT02228512
- Testing
- Pomalidomide, Rituximab, Prednisone
- Sponsor
- National Cancer Institute (NCI)
Mantle Cell Lymphoma
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with…
- Trial name
- NCT06553872
- Testing
- Pirtobrutinib, Brexucabtagene Autoleucel
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Hodgkin Lymphoma, DLBCL
Diet, Physical Activity and Body Composition Changes During R-CHOP
In this pilot study, observational data will be collected to describe the usual trajectory of changes in dietary intake, ability to be physically active, body composition, environmental exposures, and the gut microbiome over the…
- Conditions
- Non-Hodgkin Lymphoma, DLBCL, Diffuse Large B Cell Lymphoma
- Trial name
- R-CHOP-OS (NCT04293900)
- Testing
- 24-hour dietary recall, Hand grip strength, International Physical Activity Questionnaire
- Where
- United States
- Sponsor
- George Washington University
Diffuse Large-Cell Lymphoma
ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1
This study is a multicentric randomized trial evaluating the efficacy of the combination ACVBP+rituximab compared to the combination of CHOP+rituximab in patients aged from 18 to 59 years with diffuse large B-cell lymphoma and…
- Trial name
- NCT00140595
- Testing
- rituximab, doxorubicin, cyclophosphamide
- Where
- 10 sites in Belgium, France
- Volunteers
- 380 people
- Sponsor
- Lymphoma Study Association
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
This pilot study examines the safety and efficacy of anti-CD19 CAR T cells manufactured on-site in children and young adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Acute Lymphoblastic Leukemia With Failed Remission
- Trial name
- NCT05779930
- Testing
- CD19 specific Chimeric Antigen Receptor T Cell
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nationwide Children's Hospital
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
FR901228 may stop the growth of cancer cells by blocking some of the enzymes needed for cell to grow and by blocking blood flow to the cancer.
- Trial name
- NCT00383565
- Testing
- romidepsin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Marginal Zone Lymphoma(MZL)
Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
The goal of this clinical trial is to learn if Zanubrutinib, Rituximab, and Lenalidomide works to treat marginal zone lymphoma as the first-line therapy. It will also learn about the safety of the treatment.
- Trial name
- NCT07299331
- Testing
- Zanubrutinib, Rituximab, and Lenalidomide as first-line treatment for Marginal Zone Lymphoma, Zanubrutinib, Rituximab, and Lenalidomide as the primary treatment for Marginal Zone Lymphoma
- Volunteers
- 50 people
- Sponsor
- Zhengzhou University
Lymphoma
Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. It is not yet known which regimen of low-dose radiation therapy is more effective in treating follicular non-Hodgkin's lymphoma.
- Trial name
- FoRT (NCT00310167)
- Testing
- radiation therapy
- Where
- United Kingdom
- Volunteers
- 614 people
- Sponsor
- University College, London
B-Cell Acute Lymphoblastic Leukemia, Adult
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL
Clinical Trial for the Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT04788472
- Testing
- CAR-T cells targeting CD19 and CD22
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Zhejiang University
Leukemia, Lymphoma
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide in treating…
- Trial name
- NCT00020111
- Testing
- arsenic trioxide
- Where
- 52 sites in United States, Australia and 1 more
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin
A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)
This study is designed to evaluate the safety, tolerability, pharmacokinetic profile, and antitumor efficacy of DZD8586 in participants with relapsed or refractory B-NHL.
- Trial name
- NCT05844956
- Testing
- DZD8586
- Where
- 6 sites in China
- Volunteers
- 17 people
- Sponsor
- Dizal Pharmaceuticals
Leukemia, Lymphoma
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00521430
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Lymphoma
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Trial name
- NCT00372905
- Testing
- rituximab, bortezomib, Ibritumomab tiuxetan
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Northwestern University
T-NK Cell Lymphoma
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.
- Trial name
- NCT06863441
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl…
- Trial name
- NCT02003222
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab
- Where
- 544 sites in United States, Canada and 2 more
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Dementia Moderate, Dementia, Mild
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Trial name
- XanaMIA (NCT06125951)
- Testing
- Xanamem
- Where
- 34 sites in United States, Australia
- Volunteers
- 247 people
- Sponsor
- Actinogen Medical
Diffuse Large B Cell Lymphoma
Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL
Despite the current advances in clinical oncology, the prognosis of patients with resistant diffuse large B cell lymphoma or relapse after high dose chemotherapy is dismal.
- Trial name
- BeGeRN (NCT03259529)
- Testing
- Bendamustine hydrochloride, Gemcitabine 500 mg, Gemcitabine 700 mg
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Lymphoma, B-Cell, Leukemia, B-Cell
CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
The main purpose of this study is to explore the efficacy of CD19-targeted CAR-T cell therapy for minimal residual disease (MRD) in B-cell Malignancies after autologous stem cell transplantation.
- Conditions
- Lymphoma, B-Cell, Leukemia, B-Cell, Minimal Disease, Residual
- Trial name
- NCT03564977
- Testing
- CD19-targeted CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Qingdao Central Hospital
B-cell Lymphoma, Hodgkin Lymphoma
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma
This study aims to assess the feasibility of predicting patient outcomes at 1 year and 2 years after the end of first-line treatment using "liquid biopsy" (monitoring of circulating tumor DNA, ctDNA), compared to the currently…
- Trial name
- CELERITY (NCT06744075)
- Testing
- Blood assessment
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- Centre Henri Becquerel